Literature DB >> 8841152

The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.

D A Capon1, F Bochner, N Kerry, G Mikus, C Danz, A A Somogyi.   

Abstract

OBJECTIVES: We studied the disposition of dextromethorphan in extensive and poor metabolizer subjects, as well as the effect of this polymorphism on the antitussive action of dextromethorphan.
METHODS: Six extensive metabolizers were studied on four occasions: (1) after 30 mg dextromethorphan, (2) after 30 mg dextromethorphan 1 hour before 50 mg quinidine, (3) after placebo, and (4) after 50 mg quinidine. Six poor metabolizers were studied on two occasions: (1) after 30 mg dextromethorphan and (2) after placebo. Blood and urine were collected over 168 hours and assayed for dextromethorphan, total (conjugated and unconjugated) dextrorphan, 3-methoxymorphinan, and total 3-hydroxymorphinan. On each occasion at each blood sampling time, capsaicin was administered as an aerosol to provoke cough.
RESULTS: Dextromethorphan area under the plasma concentration-time curve (AUC) was 150-fold greater in the poor metabolizers than in the extensive metabolizers, and quinidine increased the AUC in extensive metabolizers 43-fold. The median dextromethorphan half-life was 19.1 hours in poor metabolizers, 5.6 hours in extensive metabolizers given quinidine, and 2.4 hours in extensive metabolizers. For dextrorphan (as total), the AUC was reduced 8.6-fold in poor metabolizers; quinidine had no effect on the AUC. The median half-life was 10.1 hours in poor metabolizers, 6.6 hours in extensive metabolizers given quinidine, and 1.4 hours in extensive metabolizers. The apparent partial clearance of dextromethorphan to dextrorphan was 1.2 L/hr in poor metabolizers, 78.5 L/hr in extensive metabolizers given quinidine, and 970 L/hr in extensive metabolizers. There was a strong (r2 = 0.82) and significant (p < 0.01) positive correlation between the prestudy urinary metabolic ratios and the partial clearances of dextromethorphan to dextrorphan. There was very large intersubject variability in responsiveness to capsaicin. There was no difference in the capsaicin-induced cough frequency in the three groups. Dextromethorphan had no antitussive effect in this experimental cough model.
CONCLUSION: The disposition of dextromethorphan was substantially influenced by CYP2D6 status. Capsaicin may not be an ideal agent in experimental cough studies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8841152     DOI: 10.1016/S0009-9236(96)90056-9

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  34 in total

1.  Classifying drug interactions.

Authors:  J K Aronson
Journal:  Br J Clin Pharmacol       Date:  2004-10       Impact factor: 4.335

2.  Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers.

Authors:  Kerri A Schoedel; Laura E Pope; Edward M Sellers
Journal:  Clin Drug Investig       Date:  2012-03-01       Impact factor: 2.859

3.  Comparative effects of dextromethorphan and dextrorphan on nicotine discrimination in rats.

Authors:  M Jerry Wright; Robert E Vann; Thomas F Gamage; M Imad Damaj; Jenny L Wiley
Journal:  Pharmacol Biochem Behav       Date:  2006-11-16       Impact factor: 3.533

Review 4.  Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping.

Authors:  D Frank; U Jaehde; U Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2007-02-02       Impact factor: 2.953

5.  Pharmacokinetic profile of dextromethorphan hydrobromide in a syrup formulation in children and adolescents.

Authors:  Eric Guenin; Marianna Armogida; Dennis Riff
Journal:  Clin Drug Investig       Date:  2014-09       Impact factor: 2.859

6.  Quantitative prediction of cytochrome P450 (CYP) 2D6-mediated drug interactions.

Authors:  Michel Tod; Sylvain Goutelle; Fannie Clavel-Grabit; Grégoire Nicolas; Bruno Charpiat
Journal:  Clin Pharmacokinet       Date:  2011-08       Impact factor: 6.447

7.  A Model for Predicting the Interindividual Variability of Drug-Drug Interactions.

Authors:  M Tod; L Bourguignon; N Bleyzac; S Goutelle
Journal:  AAPS J       Date:  2016-12-06       Impact factor: 4.009

8.  Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition.

Authors:  A A Moghadamnia; A Rostami-Hodjegan; R Abdul-Manap; C E Wright; A H Morice; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

9.  A randomized placebo controlled trial to evaluate the effects of butamirate and dextromethorphan on capsaicin induced cough in healthy volunteers.

Authors:  Shoaib Faruqi; Caroline Wright; Rachel Thompson; Alyn H Morice
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

10.  A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women.

Authors:  Alice Ban Ke; Srikanth C Nallani; Ping Zhao; Amin Rostami-Hodjegan; Nina Isoherranen; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2013-01-25       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.